Market cap
₹67,868 Cr
Recently Viewed
Clear AllNSE: GLENMARK | BSE: 532296
₹2,403.70
₹78.60
(3.38%)
As on 28-Apr-2026IST
Market cap
₹67,868 Cr
Revenue (TTM)
₹16,468 Cr
P/E Ratio
63.7
P/B Ratio
6.8
Div. Yield
0.1 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹1,065 Cr
ROE
12.6 %
ROCE
16.2 %
Industry P/E
46.42
EV/EBITDA
14.2
Debt to Equity
0.2
Book Value
₹353.8
EPS
₹87
Face value
1
Shares outstanding
282,200,809
CFO
₹7,139.14 Cr
EBITDA
₹17,959.50 Cr
Net Profit
₹5,447.10 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
| 18.1 | 10.7 | 20.2 | 76.7 | 63.4 | 33.8 | 11.3 |
|
*
| -- | -- | -- | -- | -- | -- | -- |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
| 26.1 | 88.1 | 101.3 | -19.8 | 5.2 | 42.8 | -49.8 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glenmark Pharmaceuticals
|
2,403.7 | 67,867.9 | 16,468.1 | 1,065.0 | 23.2 | 26.6 | 63.7 | 6.8 |
| 2,467.8 | 20,207.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 70.4 | 13.3 | |
| 705.2 | 17,470.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 32 | 3.9 | |
| 942.5 | 14,987.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.6 | 2.3 | |
| 1,090.5 | 58,866.0 | 6,721.6 | 841.8 | 18.1 | 18.2 | 69.8 | 11.6 | |
| 1,094.1 | 19,596.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,763.0 | 20,205.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1005.2 | 3.5 | |
| 164.5 | 21,839.6 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.7 | |
| 440.3 | 17,729.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.4 | 3.7 | |
| 1,417.3 | 23,027.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1046.7 | 5.0 |
IPO update: Glenmark Life Sciences
4 min read•By Danish Khanna
1 min read•By Research Desk
2 min read•By Value Research
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic... formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India. Read more
Incorporated
1977
Chairman
Glenn Saldanha
Managing Director
Glenn Saldanha
Group
Glenmark
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Glenmark Pharmaceuticals Ltd is ₹2,403.70 (NSE) and ₹2,404.95 (BSE) as of 28-Apr-2026 IST. Glenmark Pharmaceuticals Ltd has given a return of 63.38% in the last 3 years.
The P/E ratio of Glenmark Pharmaceuticals Ltd is 63.72 times as on 28-Apr-2026, a 37 premium to its peers’ median range of 46.42 times.
The P/B ratio of Glenmark Pharmaceuticals Ltd is 6.80 times as on 28-Apr-2026, a 82 premium to its peers’ median range of 3.73 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
41.50
|
4.92
|
|
2024
|
0.00
|
3.45
|
|
2023
|
44.14
|
1.39
|
|
2022
|
13.25
|
1.38
|
|
2021
|
13.51
|
1.86
|
The 52-week high and low of Glenmark Pharmaceuticals Ltd are Rs 2,427.40 and Rs 1,355.40 as of 29-Apr-2026.
Glenmark Pharmaceuticals Ltd has a market capitalisation of ₹ 67,868 Cr as on 28-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Glenmark Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.